Tumor necrosis factor-α inhibitor-induced morphea and psoriasiform dermatitis in a pediatric patient with Crohn's disease

被引：2

作者：

Reinhart, Jacob P. ^{[1
]}

Aird, Jenna L. ^{[1
]}

Stephens, Michael C. ^{[2
]}

Asch, Sarah ^{[3
]}

Orandi, Amir B. ^{[4
]}

Tollefson, Megha M. ^{[1
]}

机构：

[1] Mayo Clin, Dept Dermatol, 200 1st SW, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Pediat Gastroenterol, Rochester, MN 55905 USA

[3] Hometown Pediat Dermatol, North Oaks, MN USA

[4] Mayo Clin, Dept Pediat Rheumatol, Rochester, MN 55905 USA

来源：

PEDIATRIC DERMATOLOGY | 2023年 / 40卷 / 03期

关键词：

inflammatory bowel diseases; infliximab; lichen sclerosus et atrophicus; scleroderma; localized; tumor necrosis factor inhibitors; INFLAMMATORY-BOWEL-DISEASE; LICHEN-SCLEROSUS; ADALIMUMAB; THERAPY;

D O I：

10.1111/pde.15182

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Tumor necrosis factor-alpha inhibitor therapy for inflammatory bowel disease may be associated with paradoxical cutaneous adverse events, most commonly psoriasiform eruptions. We present the case of a pediatric female patient with Crohn's disease who developed multiple concurrent cutaneous eruptions while on infliximab treatment, including morphea, psoriasiform dermatitis, and genital lichen sclerosus. Although refractory to skin-directed treatments, all three conditions resolved upon discontinuation of infliximab, supporting their development as a paradoxical reaction to infliximab therapy.

引用

页码：519 / 522

页数：4

共 50 条

[41] A retrospective, observational study to examine the effect of early tumor necrosis factor inhibitor use on rates of surgery for Crohn's disease in Japan [J].

Ishida, Tetsuya .

BMC GASTROENTEROLOGY, 2025, 25 (01)

[42] Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report [J].

Feagan, Brian G. ;

Lemann, Marc ;

Befrits, Ragnar ;

Connell, William ;

D'Haens, Geert ;

Ghosh, Subrata ;

Michetti, Pierre ;

Ochsenkuehn, Thomas ;

Panaccione, Remo ;

Schreiber, Stefan ;

Silverberg, Mark ;

Sorrentino, Dario ;

van der Woude, C. Janneke ;

Vermeire, Severine ;

Rutgeerts, Paul .

INFLAMMATORY BOWEL DISEASES, 2012, 18 (01) :152-160

[43] Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease [J].

Bouguen, Guillaume ;

Huguet, Audrey ;

Amiot, Aurelien ;

Viennot, Stephanie ;

Cholet, Franck ;

Nachury, Maria ;

Flamant, Mathurin ;

Reimund, Jean-Marie ;

Desfourneaux, Veronique ;

Boureille, Arnaud ;

Siproudhis, Laurent .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (03) :628-636

[44] Effectiveness and Safety of lmmunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease [J].

Osterman, Mark T. ;

Haynes, Kevin ;

Delzell, Elizabeth ;

Zhang, Jie ;

Bewtra, Meenakshi ;

Brensinger, Colleen M. ;

Chen, Lang ;

Xie, Fenglong ;

Curtis, Jeffrey R. ;

Lewis, James D. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) :1293-+

[45] Long-term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti-tumor necrosis factor failure [J].

Yamamoto, Yoko ;

Takeuchi, Ichiro ;

Shimizu, Hirotaka ;

Fujikawa, Hiroki ;

Toda, Masanori ;

Miyata, Eri ;

To, Hiroaki ;

Nagata, Satoru ;

Arai, Katsuhiro .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (01) :123-132

[46] Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas [J].

De Gregorio, Michael ;

Lee, Tanya ;

Krishnaprasad, Krupa ;

Amos, Gregory ;

An, Yoon-Kyo ;

Bastian-Jordan, Matthew ;

Begun, Jakob ;

Borok, Nira ;

Brown, Dougal J. M. ;

Cheung, Wa ;

Connor, Susan J. ;

Gerstenmaier, Jan ;

Gilbert, Lauren E. ;

Gilmore, Robert ;

Gu, Bonita ;

Kutaiba, Numan ;

Lee, Allan ;

Mahy, Gillian ;

Srinivasan, Ashish ;

Thin, Lena ;

Thompson, Alexander J. ;

Welman, Christopher J. ;

Yong, Eric X. Z. ;

De Cruz, Peter ;

van Langenberg, Daniel ;

Sparrow, Miles P. ;

Ding, Nik S. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (06) :1306-1314

[47] Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-α Monoclonal Antibody Treatment for Crohn's Disease [J].

Matsuoka, Katsuyoshi ;

Kanai, Takanori .

DIGESTION, 2013, 88 (01) :17-19

[48] Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist [J].

Holko, Przemyslaw ;

Kawalec, Pawel ;

Pilc, Andrzej .

PHARMACOECONOMICS, 2018, 36 (07) :853-865

[49] Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-α inhibitor-induced psoriasis: A case-control study [J].

Ya, Jason ;

Hu, Jeffery Z. ;

Nowacki, Amy S. ;

Khanna, Urmi ;

Mazloom, Sean ;

Kabbur, Gowri ;

Husni, M. Elaine ;

Fernandez, Anthony P. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) :1599-1605

[50] Systematic review and meta-analysis on the association of tuberculosis in Crohn's disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα) [J].

Cao, Brent L. ;

Qasem, Ahmad ;

Sharp, Robert C. ;

Abdelli, Latifa S. ;

Naser, Saleh A. .

WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (25) :2764-2775

← 1 2 3 4 5 →